Gene therapy for alpha-1 antitrypsin deficiency

Human Molecular Genetics

Volumn 20, Issue , 2011, Pages

  Flotte, Terence R ^a   Mueller, Christian ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTICHYMOTRYPSIN;

ALPHA ANTITRYPSIN DEFICIENCY; ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; GENE MUTATION; GENE THERAPY; HUMAN; INFLAMMATION; LIVER CELL; LIVER DISEASE; LUNG DISEASE; LUNG EMPHYSEMA; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; GENE THERAPY; HEPATOCYTES; HUMANS; LIVER DISEASES; LUNG DISEASES;

EID: 79956000587     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr156     Document Type: Article

References (24)

1. Song, H.K., Lee, K.N., Kwon, K.S., Yu, M.H. and Suh, S.W. (1995) Crystal structure of an uncleaved alpha 1-antitrypsin reveals the conformation of its inhibitory reactive loop. FEBS Lett., 377, 150-154.
2. Lomas, D.A. (1994) Loop-sheet polymerization: the structural basis of Z alpha 1- antitrypsin accumulation in the liver. Clin. Sci. (Colch), 86, 489-495.
3. Huntington, J.A., Pannu, N.S., Hazes, B., Read, R.J., Lomas, D.A. and Carrell, R.W. (1999) A 2.6 ? structure of a serpin polymer and implications for conformational disease. J. Mol. Biol., 293, 449-455.
4. Sharp, H.L., Bridges, R.A., Krivit, W. and Freier, E.F. (1969) Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J. Lab. Clin. Med., 73, 934-939.
5. Sveger, T. (1976) Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N. Engl. J. Med., 294, 1316-1321.
6. Lawless, M.W., Greene, C.M., Mulgrew, A., Taggart, C.C., O'Neill, S.J. and McElvaney, N.G. (2004) Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J. Immunol., 172, 5722-5726.
7. Hidvegi, T., Schmidt, B.Z., Hale, P. and Perlmutter, D.H. (2005) Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. J. Biol. Chem., 280, 39002-39015.
8. Teckman, J.H. and Perlmutter, D.H. (2000) Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am. J. Physiol. Gastrointest. Liver Physiol., 279, G961-G974.
9. Brigham, K.L., Lane, K.B., Meyrick, B., Stecenko, A.A., Strack, S., Cannon, D.R., Caudill, M. and Canonico, A.E. (2000) Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum. Gene Ther., 11, 1023-1032.
10. Song, S., Morgan, M., Ellis, T., Poirier, A., Chesnut, K., Wang, J., Brantly, M., Muzyczka, N., Byrne, B.J., Atkinson, M. et al. (1998) Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl Acad. Sci. USA, 95, 14384-14388.
11. Brantly, M.L., Spencer, L.T., Humphries, M., Conlon, T.J., Spencer, C.T., Poirier, A., Garlington, W., Baker, D., Song, S., Berns, K.I. et al. (2006) Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther., 17, 1177-1186.
12. Louboutin, J.P., Wang, L. and Wilson, J.M. (2005) Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med., 7, 442-451.
13. Gao, G.P., Alvira, M.R., Wang, L., Calcedo, R., Johnston, J. and Wilson, J.M. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. USA, 99, 11854-11859.
14. Mueller, C., Braag, S.A., Martino, A.T., Tang, Q., Campbell-Thompson, M. and Flotte, T.R. (2009) The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr(2/2)-dependent allergy mouse model. Gene Ther., 16, 172-183.
15. Brantly, M.L., Chulay, J.D., Wang, L., Mueller, C., Humphries, M., Spencer, L.T., Rouhani, F., Conlon, T.J., Calcedo, R., Betts, M.R. et al. (2009) Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl Acad. Sci. USA, 106, 16363-16368.
16. Chulay, J.D., Ye, G.J., Thomas, D.L., Knop, D.R., Benson, J.M., Hutt, J.A., Wang, G., Humphries, M. and Flotte, T.R. (2011) Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum. Gene Ther., 22, 155-165.
17. Zern, M.A., Ozaki, I., Duan, L., Pomerantz, R., Liu, S.L. and Strayer, D.S. (1999) A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther., 6, 114-120.
18. Duan, Y.Y., Wu, J., Zhu, J.L., Liu, S.L., Ozaki, I., Strayer, D.S. and Zern, M.A. (2004) Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors. Gastroenterology, 127, 1222-1232.
19. Ozaki, I., Zern, M.A., Liu, S., Wei, D.L., Pomerantz, R.J. and Duan, L. (1999) Ribozyme-mediated specific gene replacement of the alpha1-antitrypsin gene in human hepatoma cells. J. Hepatol., 31, 53-60.
20. Cruz, P.E., Mueller, C., Cossette, T.L., Golant, A., Tang, Q., Beattie, S.G., Brantly, M., Campbell-Thompson, M., Blomenkamp, K.S., Teckman, J.H. et al. (2007) In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab. Invest., 87, 893-902.
21. Grimm, D., Streetz, K.L., Jopling, C.L., Storm, T.A., Pandey, K., Davis, C.R., Marion, P., Salazar, F. and Kay, M.A. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 441, 537-541.
22. Grimm, D., Pandey, K. and Kay, M.A. (2005) Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol., 392, 381-405.
23. McBride, J.L., Boudreau, R.L., Harper, S.Q., Staber, P.D., Monteys, A.M., Martins, I., Gilmore, B.L., Burstein, H., Peluso, R.W., Polisky, B. et al. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl Acad. Sci. USA, 105, 5868-5873.
24. Giering, J.C., Grimm, D., Storm, T.A. and Kay, M.A. (2008) Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol. Ther., 16, 1630-1636.